Difference between revisions of "Part:BBa K274002:Experience"

(Applications of BBa_K274002)
(User Reviews)
Line 28: Line 28:
 
<!-- End of the user review template -->
 
<!-- End of the user review template -->
 
<!-- DON'T DELETE --><partinfo>BBa_K274002 EndReviews</partinfo>
 
<!-- DON'T DELETE --><partinfo>BBa_K274002 EndReviews</partinfo>
 +
 +
Sequence analysis of this part reveals that there is a SpeI site where the XbaI site should be.  In addition there is insufficient length between the BioBrick sites (i.e. this is not a standard prefix) to allow efficient cutting of both restriction endonucleases. -- Mike Speer
  
 
Andrew Kirk, undergraduate, Penn State iGEM 2010
 
Andrew Kirk, undergraduate, Penn State iGEM 2010

Revision as of 05:11, 7 November 2011


[http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia] has analysed products of this part along with products of Part:BBa_K274004 by thin-layer chromatography and mass spectrometry (for a detailed description of the procedures see the 2010 iGEM team Slovenia [http://2010.igem.org/Team:Slovenia/METHODS_and_PARTS/protocols/bm#TLC wiki]). Unfortunately we had problems with transformation of Part:BBa_K274002 in E.coli, so we constructed our own vio operon from Part:BBa_K274003, Part:BBa_B0034 and a vioC gene, amplified by PCR from Part:BBa_K274004. Transcription of the construct therefore resulted in same proteins as Part:BBa_K274002.

Figure: TLC separation of culture extracts on a silica gel HPTLC plate under white light and UV light.

Results of our experiments show that both of the tested constructs lead to synthesis of three main compounds, namely violacein, deoxyviolacein and deoxychromoviridans (this was confirmed with standards and MS). Part:BBa_K274002 produces a large amount of deoxyviolacein, and smaller amounts of violacein and deoxychromoviridans, while Part:BBa_K274004 results in production of deoxychromoviridans and some deoxyviolacein rather than violacein.

Judging by the violacein biosynthesis pathways scheme uploaded on the main page, the results imply that spontaneous transformations of intermediates in the violacein biosynthetic pathway occur frequently, therefore reducing the biosynthetic flow towards violacein and resulting in a lower yield of the latter. Since violacein is a potentially very applicable compound in terms of medicine and other applications (for instance natural purple dyes), it is interesting for industrial production that could be problematic because of the unwanted side products like deoxychromoviridans. That is why [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia] has decided to improve the violacein biosynthetic pathway. Therefore we designed new constructs derived from Part:BBa_K274002. We designed chimeric vio enzymes, fused with zinc finger proteins (Part:BBa_K323132 and Part:BBa_K323135). We showed higher yields of violacein production where biosynthetic enzymes are bound to zinc fingers and through them to DNA scaffold (called DNA program). DNA program was designed in such a way, that it arranges biosynthetic enzymes in a correct order, leading to close proximity which ensures higher yields of biosynthesis and decreases formation of side products. See our project on [http://2010.igem.org/Team:Slovenia 2010 iGEM team Slovenia].



Applications of BBa_K274002

The Johns Hopkins 2011 team has taken this part and retooled it for expression in S. cerevisiae. Each gene in the operon will be represented by a separate part for compatibility with eukaryotic expression. We have held off on submission to the Registry due to the presence of illegal sites that we plan to fix with quick-change PCR in the next two weeks.

User Reviews

UNIQe11acdefeebe006a-partinfo-00000000-QINU UNIQe11acdefeebe006a-partinfo-00000001-QINU

Sequence analysis of this part reveals that there is a SpeI site where the XbaI site should be. In addition there is insufficient length between the BioBrick sites (i.e. this is not a standard prefix) to allow efficient cutting of both restriction endonucleases. -- Mike Speer

Andrew Kirk, undergraduate, Penn State iGEM 2010

When designing our project, we were thinking about using the violacein pigment, K274002, in our genetic circuit. This part is supposed to be just the coding sequence. Because the tube in the picture [http://2010.igem.org/Team:Penn_State/Project#Characterization_of_Old_BioBrick_parts on our website] only this part with no promoter added, there should be no expression of violacein. However, as can be seen below, the violacein is present. This could be caused by either an undocumented promoter within the part, or a non-insulated BioBrick vector with inefficient flanking transcriptional terminators.

Karina Arnesen, undergraduate, Alberta iGEM 2010

We also failed to transform K274002. We attempted to transform K274002 from both location in the 2011 registry shipment and the 2010 registry shipment.